Exactech Announces Full Launch of Three Revision Systems & Expansion of Advanced Surgical Technologies at AAOS 2017 Annual Me...
March 14 2017 - 8:55AM
Business Wire
Exactech (Nasdaq: EXAC), a developer and producer of bone and
joint restoration products and biologic solutions for extremities,
knee and hip, announced today its lineup of products to be
showcased at the company’s educational exhibit, Booth #1433, at the
American Academy of Orthopedic Surgeons (AAOS) 2017 Annual Meeting,
March 15-17 in San Diego, Calif.
Highlights of Exactech’s latest innovations include:
- ExactechGPS®, a compact,
surgeon-controlled computer-assisted surgical technology that
delivers reproducible results in total joint arthroplasty, expands
its offerings with new knee applications, as well as the first
application for total shoulder arthroplasty*. Live demonstrations
will take place throughout the event.
- The Equinoxe® Humeral Reconstruction
Prosthesis offers a unique and stable solution for complex and
challenging shoulder arthroplasty cases with significant humeral
bone loss.** Also featured will be the new Preserve Stem, a
conservative treatment option designed for preserving humeral
bone.
- The Vantage® Total Ankle System is
Exactech’s first product in the foot and ankle market. The system
features both tibial and talar components, which were designed for
minimal bone resection and optimal support for the anatomically
shaped implant.
- The Optetrak Logic® CC Revision Knee
System offers a comprehensive portfolio to help surgeons address
challenging revision cases. Exactech’s redesigned, intuitive
instrumentation for an efficient, streamlined surgical experience
will also be showcased.
- The Alteon® Monobloc Revision Femoral
Stem is a press-fit, distally fixed, one-piece tapered, splined
titanium stem. It incorporates specific philosophies designed to
improve surgical experiences and clinical outcomes for hip
arthroplasty patients.
- The InterSpace® Tapered Wedge Hip
Spacer and data behind InterSpace’s preformed spacer technology
with 20 years of clinical experience will be showcased. The
AcuDriver® Automated Osteotome Handpiece for implant removal will
be featured in live demonstrations.
- Ossilix® is a high performance, next
generation calcium phosphate cement indicated for filling bony
defects in cancellous bone. Ossilix is fast- and hardsetting within
approximately six minutes in a 37°F wet environment. Once set, it
can be drilled and inserted with screws. In addition, the Biologics
offerings will include Reveille™ Cartilage Processor, a cost
effective option for single stage surgery with autologous
cartilage. Reveille is used for intra-operative resizing of
autologous tissue into usable particles.
Exactech will showcase new clinical data in the Journal of
Shoulder and Elbow Surgery Compendium of Shoulder Outcomes and
Research and Exactech Knee Scientific and Clinical Evidence
booklet. Scientists and surgeon consultants will be available to
discuss the articles, as well as share their experiences on all of
the company’s latest product innovations. Attendees may also learn
about Exactech’s patient education and practice marketing program
at the booth.
Visit www.exac.com/academy for more information on featured
products, scheduled clinical experts and live demonstrations.
*The ExactechGPS Total Shoulder Application is currently
undergoing premarket review by the FDA. It is intended for use
during preoperative planning and during stereotaxic surgery to aid
the surgeon in locating anatomical structures and aligning the
endoprostheses with the anatomical structures.
**The Equinoxe Humeral Reconstruction Prosthesis is not
indicated for use with the reverse shoulder components in oncology
applications.
About Exactech
Based in Gainesville, Fla., Exactech develops and markets
orthopaedic implant devices, related surgical instruments and
biologic materials and services to hospitals and physicians. The
company manufactures many of its orthopaedic devices at its
Gainesville facility. Exactech’s orthopaedic products are used in
the restoration of bones and joints that have deteriorated as a
result of injury or diseases such as arthritis. Exactech markets
its products in the United States, in addition to more than 30
markets in Europe, Latin America, Asia and the Pacific. Additional
information about Exactech can be found at http://www.exac.com.
A current investment profile on Exactech (Nasdaq: EXAC) is
available online at http://www.hawkassociates.com/profile/exac.cfm.
To receive future releases in e-mail alerts, sign up at
http://www.hawkassociates.com/about/alert.
This release contains various forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934, which represent
the company’s expectations or beliefs concerning future events of
the company’s financial performance. These forward-looking
statements are further qualified by important factors that could
cause actual results to differ materially from those in the
forward-looking statements. These factors include the effect of
competitive pricing, the company’s dependence on the ability of
third party manufacturers to produce components on a basis which is
cost-effective to the company, market acceptance of the company’s
products and the effects of government regulation. Results actually
achieved may differ materially from expected results included in
these statements.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170314005302/en/
ExactechInvestor contactsJody Phillips, 352-377-1140Executive
Vice President of Finance &Chief Financial OfficerorHawk
AssociatesJulie Marshall or Frank Hawkins,
305-451-1888EXAC@hawkassociates.comorMedia
contactsExactechPriscilla Bennett, 352-377-1140Vice President,
Corporate & Marketing Communication
Exactech, Inc. (delisted) (NASDAQ:EXAC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Exactech, Inc. (delisted) (NASDAQ:EXAC)
Historical Stock Chart
From Apr 2023 to Apr 2024